International health care and compensation systems experienced a radical transformation in the 2000s, resulting from growing fiscal pressures incited by economic depression and also a steady rise in health care spending.
Novartis' Gilenya Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries' Health Care Systems Case Study Solution
This phenomenon was most pronounced in America, where the well-being-spending share of GDP grew from five percent in 1960 to 17.9 percent in 2011. Although specifics changed by nation, the systemic evolution of international health care and compensation standards was defined by two main trends-a shift toward value-based pricing; and stringent compensation standards for new drug evaluations.
Bearing this in mind, each country developed its own methods and decision making procedures for reimbursing companies looking to penetrate its market with new inventions. Germany, the United Kingdom, and Japan exemplified this dynamic.
PUBLICATION DATE: January 06, 2014 PRODUCT #: E489-HCB-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Impact of TPL on E-Commerce
Transportation of Pratt & Whitney north heaven (Abridged)
Saudi Aramco Oil Company
Conseco: Market Assumptions and Risk
A Better Yoga Block: Shanti Creek Yoga Products
Belton Semiconductors (A)
New River Apparel: Trot or Gallop?
Relay Foods: Media Mix1
Japan 1995: Return to High Performance?
The Buenos Aires-Colonia Bridge (A): The Project
